Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,665 across all filing types
Latest filing 2012-07-02 Regulatory Filings
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Allied and CSIRO announce stem cell collaboration 2 pages 259.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 3 July 2012 about a research collaboration between Allied Healthcare Group and CSIRO focusing on stem cell technology for heart failure. It describes the collaboration, technology, and potential commercial applications. There are no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, and no mention of report attachments or certifications. The content is a corporate announcement about a new research collaboration and technology development, which does not fit into categories like Annual Report, Interim Report, Earnings Release, or others related to financial or governance disclosures. It is a general regulatory announcement about company activities and partnerships, best classified under Regulatory Filings (RNS). The document length is 7642 characters, which is sufficient for a substantive announcement but not a full report.
2012-07-02 English
Appendix 3B 8 pages 388.4KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B – Issue of Shares' and is an official announcement to the Australian Stock Exchange (ASX) regarding the allotment of 22,000 shares at an issue price of $0.03 as part of a Rights Issue. It includes detailed information about the share issue, terms, dates, and quotation agreement. The document is a formal notification of a new share issue and application for quotation of additional securities, consistent with regulatory requirements for capital changes. It does not contain financial statements or performance data, nor is it a report or presentation. Therefore, it fits the category of a Share Issue/Capital Change announcement.
2012-06-20 English
Allied submits CE Mark application for CardioCel 2 pages 76.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated June 5, 2012, regarding Allied Healthcare Group submitting a CE Mark application for its CardioCel cardiovascular patch. The content focuses on regulatory submission and product commercialization strategy, with no financial data, earnings, or management discussion. It is a corporate announcement about a regulatory milestone rather than a financial report or detailed investor presentation. The document length is about 5906 characters, which is relatively short and consistent with an announcement. There is no indication of it being a report, certification, or detailed financial disclosure. Therefore, the most appropriate classification is a Regulatory Filing (RNS), as it is a general regulatory announcement that does not fit into other specific categories.
2012-06-04 English
Appendix 3B 8 pages 201.1KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B – Issue of Unlisted Options' and is an announcement from Allied Healthcare Group Ltd regarding the allotment of 5,800,000 unlisted options to new executives. It includes detailed information about the securities issued, their terms, and compliance with ASX listing rules. The document is a formal notification of a new securities issue and application for quotation on the Australian Stock Exchange. It does not contain financial statements, management discussion, or audit information. It is not a report but an announcement of a capital change event (issue of new securities). Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail confirm it is not a brief notice but a full announcement of a capital issuance event.
2012-05-21 English
Initial Director`s Interest Notice 2 pages 11.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including unlisted options, and states the date of appointment of the director. The content is focused on disclosure of personal share transactions or interests by a company director. There is no financial report, earnings data, or management discussion. The document length is about 3,054 characters, which is consistent with a director's dealing notice rather than a full report or announcement. Therefore, this document fits the category of Director's Dealing (DIRS).
2012-05-21 English
Director Appointment/Resignation 2 pages 185.1KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement about the appointment of a new non-executive director and the retirement of an existing board member. It focuses on changes in the company's board of directors, mentioning the names, backgrounds, and roles of the individuals involved. There is no financial data, report publication, or regulatory filing content. The document fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2012-05-17 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.